Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization

Journal of Clinical Microbiology

Volumn 43, Issue 6, 2005, Pages 2886-2894

  Laassri, Majid ^a   Dragunsky, Eugenia ^a   Enterline, Joan ^a   Eremeeva, Tatiana ^b   Ivanova, Olga ^b   Lottenbach, Kathleen ^c   Belshe, Robert ^c   Chumakov, Konstantin ^a,d  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^c SAINT LOUIS UNIVERSITY   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ORAL POLIOMYELITIS VACCINE;

ACUTE DISEASE; ARTICLE; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; DNA MICROARRAY; ERADICATION THERAPY; FECES ANALYSIS; FLACCID PARALYSIS; GENETIC VARIABILITY; HUMAN; INFANT; NUCLEOTIDE SEQUENCE; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS STRAIN; VIRUS TRANSMISSION;

DNA, COMPLEMENTARY; FECES; GENOME, VIRAL; HUMANS; INFANT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

POLIOVIRUS;

EID: 20444433546     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.6.2886-2894.2005     Document Type: Article

References (54)

1. Abraham, R., P. Minor, G. Dunn, J. F. Modlin, and P. L. Ogra. 1993. Shedding of virulent poliovirus revenants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J. Infect. Dis. 168:1105-1109.
2. Blomqvist, S., C. Savolainen, P. Laine, P. Hirttio, E. Lamminsalo, E. Penttila, S. Joks, M. Roivainen, and T. Hovi. 2004. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J. Virol. 78:4876-4883.
3. Boot, H. J., R. M. Schepp, F. J. van Nunen, and T. G. Kimman. 2004. Rapid RT-PCR amplification of full-length poliovirus genomes allows rapid discrimination between wild-type and recombinant vaccine-derived polioviruses. J. Virol. Methods 116:35-43.
4. Burgener, M., U. Candrian, and M. Gilgen. 2003. Comparative evaluation of four large-volume RNA extraction kits in the isolation of viral RNA from water samples. J. Virol. Methods 108:165-170.
5. Cann, A. J., G. Stanway, P. J. Hughes, P. D. Minor, D. M. Evans, G. C. Schild, and J. W. Almond. 1984. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 12:7787-7792.
6. Cherkasova, E., M. Laassri, V. Chizhikov, E. Korotkova, E. Dragunsky, V. I. Agol, and K. Chumakov. 2003. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc. Natl. Acad. Sci. USA 100:9398-9403.
7. Cherkasova, E. A., E. A. Korotkova, M. L. Yakovenko, O. E. Ivanova, T. P. Eremeeva, K. M. Chumakov, and V. I. Agol. 2002. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76:6791-6799.
8. Chizhikov, V., M. Wagner, A. Ivshina, Y. Hoshino, A. Z. Kapikian, and K. Chumakov. 2002. Detection and genotyping of human group A rotaviruses by oligonucleotide microarray hybridization. J. Clin. Microbiol. 40:2398-2407.
9. Christodoulou, C., F. Colbere-Garapin, A. Macadam, L. F. Taffs, S. Marsden, P. Minor, and F. Horaud. 1990. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J. Virol. 64:4922-4929.
10. Chumakov, K. M. 1996. PCR engineering of viral quasispecies: a new method to preserve and manipulate genetic diversity of RNA virus populations. J. Virol. 70:7331-7334.
11. Contreras, G., K. Dimock, J. Furesz, C. Gardell, D. Hazlett, K. Karpinski, G. McCorkle, and L. Wu. 1992. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals 20:15-26.
12. De Leon, R., S. M. Matsui, R. S. Baric, J. E. Hermann, N. R. Blacklow, H. B. Greenberg, and M. D. Sobsey. 1992. Detection of Norwalk virus in stool specimens by reverse transcriptase-polymerase chain reaction and nonradio-active oligoprobes. J. Clin. Microbiol. 30:3151-3157.
13. Domingo, E., E. Martinez-Salas, F. Sobrino, J. C. de la Torre, A. Portela, J. Ortin, C. Lopez-Galindez, P. Perez-Brena, N. Villanueva, R. Najera, et al. 1985. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance. Gene 40:1-8.
14. Dowdle, W. R., E. De Gourville, O. M. Kew, M. A. Pallansch, and D. J. Wood. 2003. Polio eradication: the OPV paradox. Rev. Med. Virol. 13:277-291.
15. Duarte, E. A., I. S. Novella, S. C. Weaver, E. Domingo, S. Wain-Hobson, D. K. Clarke, A. Moya, S. F. Elena, J. C. de la Torre, and J. J. Holland. 1994. RNA virus quasispecies: significance for viral disease and epidemiology. Infect. Agents Dis. 3:201-214.
16. Dunn, G., N. T. Begg, N. Cammack, and P. D. Minor. 1990. Virus excretion and mutation by infants following primary vaccination with live oral polio-vaccine from two sources. J. Med. Virol. 32:92-95.
17. Evans, D. M., G. Dunn, P. D. Minor, G. C. Schild, A. J. Cann, G. Stanway, J. W. Almond, K. Currey, and J. V. Maizel, Jr. 1985. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550.
18. Evans, D. M., P. D. Minor, G. S. Schild, J. W. Almond, G. C. Schild, J. Bootman, M. Ferguson, P. Reeve, M. Spitz, G. Stanway, A. J. Cann, R. Hauptmann, L. D. Clarke, and R. C. Mountford. 1983. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3. Location and primary structure of a major antigenic site for poliovirus neutralization. Nature 304:459-462.
19. Friedrich, F. 1996. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virol. 40:157-170.
20. Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination. I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin. Infect. Dis. 37:241-250.
21. Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination. II. Adverse events. Clin. Infect. Dis. 37:251-271.
22. Henderson, D. A. 2002. Countering the posteradication threat of smallpox and polio. Clin. Infect. Dis. 34:79-83.
23. Jiang, X., J. Wang, D. Y. Graham, and M. K. Estes. 1992. Detection of Norwalk virus in stool by polymerase chain reaction. J. Clin. Microbiol. 30:2529-2534.
24. Kawamura, N., M. Kohara, S. Abe, T. Komatsu, K. Tago, M. Arita, and A. Nomoto. 1989. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1302-1309.
25. Kew, O., V. Morris-Glasgow, M. Landaverde, C. Burns, J. Shaw, Z. Garib, J. Andre, E. Blackman, C. J. Freeman, J. Jorba, R. Sutter, G. Tambini, L. Venczel, C. Pedreira, F. Laender, H. Shimizu, T. Yoneyama, T. Miyamura, H. van Der Avoort, M. S. Oberste, D. Kilpatrick, S. Cochi, M. Pallansch, and C. deq Uadros. 2002. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296:356-359.
26. Khetsuriani, N., D. R. Prevots, L. Quick, M. E. Elder, M. Pallansch, O. Kew, and R. W. Sutter. 2003. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 188:1845-1852.
27. Korotkova, E. A., R. Park, E. A. Cherkasova, G. Y. Lipskaya, K. M. Chumakov, E. V. Feldman, O. M. Kew, and V. I. Agol. 2003. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J. Virol. 77:12460-12465.
28. Laassri, M., V. Chizhikov, M. Mikheev, S. Shchelkunov, and K. Chumakov. 2003. Detection and discrimination of orthopoxviruses using microarrays of immobilized oligonucleotides. J. Virol. Methods 112:67-78.
29. Landaverde, M., L. Venczel, and C. A. deq Uadros. 2001. Poliomyelitis outbreak caused by vaccine-derived virus in Haiti and the Dominican Republic. Rev. Panam. Salud Publ. 9:272-274.
30. Macadam, A. J., S. R. Pollard, G. Ferguson, R. Skuce, D. Wood, J. W. Almond, and P. D. Minor. 1993. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18-26.
31. Macadam, A. J., D. M. Stone, J. W. Almond, and P. D. Minor. 1994. The 5′ noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol. 2:449-454.
32. Martin, J., G. Dunn, R. Hull, V. Patel, and P. D. Minor. 2000. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74:3001-3010.
33. Melnick, J. L. 1996. Current status of poliovirus infections. Clin. Microbiol. Rev. 9:293-300.
34. Minor, P. D., G. C. Schild, J. Bootman, D. M. Evans, M. Ferguson, P. Reeve, M. Spitz, G. Stanway, A. J. Cann, R. Hauptmann, L. D. Clarke, R. C. Mountford, and J. W. Almond. 1983. Location and primary structure of a major antigenic site for poliovirus neutralization. Nature 301:674-679.
35. Ogra, P. L., H. S. Faden, R. Abraham, L. C. Duffy, M. Sun, and P. D. Minor. 1991. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J. Infect. Dis. 164:191-194.
36. Old, M. O., C. V. Martinez, D. Kwock, J. Garcia, G. Martin, C. Chan, and Y. A. Maldonado. 2003. Direct extraction of Sabin poliovirus genomes from human fecal samples using a guanidine thiocyanate extraction method. J. Virol. Methods 110:193-200.
37. Paul, Y., B. D. Schoub, J. Martin, G. Dunn, R. Hull, V. Patel, P. D. Minor, and S. C. Arya. 2001. Medical negligence and vaccine associated paralytic poliomyelitis. Indian Pediatr. 38:1068-1069.
38. Prevots, D. R., and P. M. Strebel. 1997. Poliomyelitis prevention in the United States: new recommendations for routine childhood vaccination place greater reliance on inactivated poliovirus vaccine. Pediatr. Ann. 26:378-383.
39. Rennels, M. B., J. A. Englund, D. I. Bernstein, G. A. Losonsky, E. L. Andersen, M. E. Pichichero, F. M. Munoz, and M. C. Wolff. 2000. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr. Infect. Dis. J. 19:417-423.
40. Rousset, D., M. Rakoto-Andrianarivelo, R. Razafindratsimandresy, B. Randriamanalina, S. Guillot, J. Balanant, P. Mauclere, and F. Delpeyroux. 2003. Recombinant vaccine-derived poliovirus in Madagascar. Emerg. Infect. Dis. 9:885-887.
41. Strebel, P. M., R. W. Sutter, S. L. Cochi, R. J. Biellik, E. W. Brink, O. M. Kew, M. A. Pallansch, W. A. Orenstein, and A. R. Hinman. 1992. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14:568-579.
42. Tatem, J. M., C. Weeks-Levy, S. J. Mento, S. J. DiMichele, A. Georgiu, W. F. Waterfield, B. Sheip, C. Costalas, T. Davies, M. B. Ritchey, et al. 1991. Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees. J. Med. Virol 35:101-109.
43. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
44. Widjojoatmodjo, M. N., A. C. Fluit, R. Torensma, G. P. Verdonk, and J. Verhoef. 1992. The magnetic immuno polymerase chain reaction assay for direct detection of salmonellae in fecal samples. J. Clin. Microbiol. 30:3195-3199.
45. Wilde, J., J. Eiden, and R. Yolken. 1990. Removal of inhibitory substances from human fecal specimens for detection of group A rotaviruses by reverse transcriptase and polymerase chain reactions. J. Clin. Microbiol. 28:1300-1307.
46. Wood, D. J. 2001. The scientific basis for stopping polio immunisation-issues and challenges. Dev. Biol. (Basel) 105:69-72.
47. Wood, D. J., R. W. Sutter, and W. R. Dowdle. 2000. Stopping poliovirus vaccination after eradication: issues and challenges. Bull. W. H. O. 78:347-357.
48. World Health Organization. 2001. Acute flaccid paralysis associated with circulating vaccine-derived poliovirus. Philippines, 2001. Wkly. Epidemiol. Rec 76:319-320.
49. World Health Organization. 2001. Circulation of a type 2 vaccine-derived poliovirus-Egypt, 1982-1993. Morb. Mortal. Wkly. Rep. 50:41-42, 51.
50. World Health Organization. 1997. Manual for the virologic investigation of poliomyelitis. W.H.O./EPI/GEN/97.1. World Health Organization, Geneva, Switzerland.
51. World Health Organization. 2002. Paralytic poliomyelitis in Madagascar. 2002. Wkly. Epidemiol. Rec. 77:241-242.
52. World Health Organization. 2001. Polio laboratory manual. World Health Organization, Geneva, Switzerland.
53. World Health Organization. 2002. W.H.O. global action plan for laboratory containment of wild polioviruses, 2nd ed. World Health Organization, Geneva, Switzerland.
54. Yang, C. F., T. Naguib, S. J. Yang, E. Nasr, J. Jorba, N. Ahmed, R. Campagnoli, H. van der Avoort, H. Shimizu, T. Yoneyama, T. Miyamura, M. Pallansch, and O. Kew. 2003. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J. Virol. 77:8366-8377.